- Home
- ACON vs BDRX Comparison
ACON vs BDRX Comparison
Compare ACON & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- BDRX
- Stock Information
- Founded
- ACON 2008
- BDRX 2000
- Country
- ACON United States
- BDRX United Kingdom
- Employees
- ACON N/A
- BDRX 13
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- BDRX Health Care
- Exchange
- ACON Nasdaq
- BDRX Nasdaq
- Market Cap
- ACON 4.5M
- BDRX 3.9M
- IPO Year
- ACON 2022
- BDRX N/A
- Fundamental
- Price
- ACON $7.80
- BDRX $6.71
- Analyst Decision
- ACON Buy
- BDRX
- Analyst Count
- ACON 2
- BDRX 0
- Target Price
- ACON $481.00
- BDRX N/A
- AVG Volume (30 Days)
- ACON 8.1K
- BDRX 53.1K
- Earning Date
- ACON 11-13-2025
- BDRX 09-23-2025
- Dividend Yield
- ACON N/A
- BDRX N/A
- EPS Growth
- ACON N/A
- BDRX N/A
- EPS
- ACON N/A
- BDRX N/A
- Revenue
- ACON $62,948.00
- BDRX N/A
- Revenue This Year
- ACON $145.39
- BDRX N/A
- Revenue Next Year
- ACON $145.45
- BDRX N/A
- P/E Ratio
- ACON N/A
- BDRX N/A
- Revenue Growth
- ACON 16.68
- BDRX N/A
- 52 Week Low
- ACON $6.20
- BDRX $5.00
- 52 Week High
- ACON $3,499.51
- BDRX $108.90
- Technical
- Relative Strength Index (RSI)
- ACON 63.90
- BDRX 55.69
- Support Level
- ACON $7.00
- BDRX $5.81
- Resistance Level
- ACON $7.84
- BDRX $6.47
- Average True Range (ATR)
- ACON 0.28
- BDRX 0.51
- MACD
- ACON 0.07
- BDRX 0.22
- Stochastic Oscillator
- ACON 96.09
- BDRX 81.44
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.